Arcturus Therapeutics (ARCT) Misses Q2 EPS by 130c, misses on revenue

Arcturus Therapeutics (NASDAQ: ARCT) reported Q2 EPS of ($1.98), $1.30 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $10.52 million versus the consensus estimate of $28.38 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• ​Trump said he was unaware of his earnings from crypto
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT
• Six Flags names Mark Pauls as chief operating officer